NEW YORK (Reuters) – The U.S. Centers for Disease Control and Prevention said on Wednesday that it had identified 28 cases of serious blood clotting among the more than 8.7 million people who had received the Johnson & Johnson (NYSE:) COVID-19 vaccine.
The CDC said in a presentation that the highest rates of thrombosis with thrombocytopenia syndrome – blood clotting combined with a low platelet count – were among women aged 30 to 49.
Only six of the clotting events identified were in men.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Be the first to comment